What is the appropriate management of osteoarthritis?

Management of Osteoarthritis

All patients with symptomatic osteoarthritis should receive three core non-pharmacological treatments: patient education, structured exercise (including muscle strengthening and aerobic fitness), and weight loss interventions if overweight or obese (BMI ≥25 kg/m²) 1.

Core Non-Pharmacological Management (Foundation for All Patients)

These interventions form the foundation of osteoarthritis management and should be implemented before or alongside any pharmacological therapy:

Patient Education and Self-Management

• Provide written and oral information to counter the misconception that osteoarthritis is inevitably progressive and untreatable 1
• Establish self-management strategies emphasizing exercise adherence 1
• Assess impact on function, quality of life, occupation, mood, relationships, and leisure activities 1

Exercise Programs

• Local muscle strengthening exercises targeting the affected joint
• General aerobic fitness activities (walking, swimming, cycling)
• Neuromuscular education 2
• Evidence shows effect sizes of 0.57 to 1.0 for exercise interventions, with benefits lasting 6-18 months 3
• Both supervised and home-based programs are effective 3

Weight Management

• Target weight loss for all patients with BMI ≥25 kg/m² 2, 4
• Sustained weight loss improves pain and function, particularly in knee osteoarthritis 4
• Combine diet and exercise approaches for optimal results 4

Pharmacological Management Algorithm

First-Line: Topical Therapy (Knee and Hand OA)

Start with topical NSAIDs before oral medications 1, 5

• Topical NSAIDs have clinical efficacy with superior safety profile compared to oral agents 1, 3
• Consider topical capsaicin as alternative 1

Second-Line: Oral NSAIDs

If topical therapy insufficient:

• Use oral NSAIDs (non-selective or COX-2 inhibitors) at lowest effective dose for shortest duration 1, 4
• Always co-prescribe proton pump inhibitor regardless of NSAID type 1
• No significant difference in gastrointestinal adverse events between selective and non-selective NSAIDs 4
• Consider individual cardiovascular, gastrointestinal, liver, and renal risk factors when selecting agent 1

Important caveat: Recent evidence shows acetaminophen (paracetamol) has very small effect sizes and may be ineffective as monotherapy for most patients 5. While older NICE guidelines 1 recommended it first-line, the 2019 ACR guideline 5 only conditionally recommends it, noting it's primarily appropriate for patients with contraindications to NSAIDs.

Third-Line: Adjunctive Systemic Agents

When NSAIDs are insufficient, contraindicated, or poorly tolerated:

Duloxetine (conditionally recommended) 5

• Effective for knee, hip, and hand OA
• Can be used alone or combined with NSAIDs
• Consider tolerability and side effect profile

Tramadol (conditionally recommended over other opioids) 5

• Reserve for patients with contraindications to NSAIDs or when other therapies ineffective
• Use lowest dose for shortest duration
• Evidence limited to <1 year of use

Non-tramadol opioids (conditionally recommended AGAINST) 5

• Avoid due to high risk of toxicity, dependence, and minimal long-term benefit
• Only consider when all alternatives exhausted 5, 4

Intra-Articular Injections

Corticosteroid Injections (Knee)

Strongly recommended for acute flares, especially with effusion 3, 4

• 19 high-quality studies support efficacy 4
• Provides short-term pain relief (typically 3 months) 4
• Preferred over other intra-articular agents based on evidence quality 5

Hyaluronic Acid Injections

Not recommended for routine use 2, 4

• Evidence inconsistent across 17 high-quality and 11 moderate-quality studies 4
• Number needed to treat = 17 patients 4
• Cannot identify which patients will benefit 4
• AAOS 2014 guideline explicitly recommends against 2

Platelet-Rich Plasma

• Limited evidence: 2 high-quality studies show benefit 4
• Worse outcomes in severe osteoarthritis 4
• Concerns regarding cost and safety profile 4

Adjunctive Physical Modalities

Consider for specific situations:

• Local heat or cold applications
• TENS (transcutaneous electrical nerve stimulation)
• Manipulation and stretching (particularly for hip OA) 1
• Bracing, joint supports, or insoles for biomechanical instability 1
• Assistive devices (walking sticks, tap turners) for activities of daily living 1
• Appropriate footwear with shock-absorbing properties 1

Treatments NOT Recommended

Do not use 1, 2, 1:

• Glucosamine or chondroitin products
• Electroacupuncture
• Acupuncture (insufficient evidence despite RCTs)

Surgical Considerations

Arthroscopy

Recommended AGAINST for osteoarthritis 4

• Exception: truly obstructing displaced meniscus tears (rare) 4
• Most meniscus tears in OA are degenerative and unlikely to improve with surgery 4

Total Joint Replacement

Consider for patients with:

• Radiographic evidence of OA
• Refractory pain and disability despite conservative management 3
• Advanced symptoms and structural damage 6

Common Pitfalls to Avoid

1. Starting with acetaminophen as primary therapy: Current evidence shows minimal benefit for most patients 5
2. Prescribing oral NSAIDs without gastroprotection: Always co-prescribe PPI 1
3. Using opioids as routine therapy: Reserve for exceptional circumstances only 5, 4
4. Performing arthroscopy for degenerative meniscus tears: Unlikely to benefit patients with established OA 4
5. Neglecting core non-pharmacological interventions: These remain the foundation regardless of pharmacological choices 1
6. Failing to assess comorbidities: Particularly important in elderly patients when selecting NSAIDs 1

Monitoring and Follow-Up

• Provide periodic review tailored to individual needs 1
• Monitor for hepatotoxicity if using acetaminophen regularly (maximum 3 gm daily) 5
• Assess cardiovascular, gastrointestinal, liver, and renal function when using NSAIDs 1
• Re-evaluate treatment plan if inadequate response after appropriate trial period